Organophosphate detoxification by membrane-engineered red blood cells

Area of Science:

• Biotechnology
• Biochemistry
• Chemical Engineering

Background:

• Biotherapeutics offer high specificity but face pharmacokinetic challenges like short half-life and degradation.
• Current treatments for organophosphate nerve agent (OPNA) exposure are limited, necessitating improved prophylactic strategies.
• Red blood cells (RBCs) are explored as a platform for enhancing biotherapeutic delivery due to their longevity and biocompatibility.

Purpose of the Study:

• To develop a novel cell-based delivery system for butyrylcholinesterase (BChE) by engineering it onto RBC membranes.
• To overcome the pharmacokinetic limitations of BChE, improving its stability and therapeutic efficacy.
• To create a robust and tunable method for attaching biotherapeutics to RBCs.

Main Methods:

• A three-step chemical engineering process was employed to conjugate BChE to RBC membranes.
• Step 1: Pre-modification of BChE with a cell-reactive polymer.
• Step 2: Priming of RBCs for conjugation.
• Step 3: Grafting of the modified BChE to the RBC surface.

Main Results:

• Over 2 million BChE molecules were successfully attached to each RBC surface.
• The engineered RBC-BChE conjugate retained the enzyme's bioscavenging activity.
• The RBC membrane engineering approach demonstrated cell tolerance with minimal hemolysis.
• Enhanced stability of BChE was observed when conjugated to RBCs.

Conclusions:

• Engineered RBCs serve as an effective enhanced biotherapeutic delivery vehicle.
• This RBC-based system offers a promising strategy for prophylactic protection against OPNA exposure.
• The described chemical engineering method is rapid, tunable, and applicable to other biotherapeutics.